LETTER

Article in PDF format - JOP Home page

JOP. J Pancreas (Online) 2009 Mar 9; 10(2):215-220.

Cardiotoxicity of 5-Fluorouracil and Capecitabine in a Pancreatic Cancer Patient with a Novel Mutation in the Dihydropyrimidine Dehydrogenase Gene

Armin Shahrokni, Mohammad Reza Rajebi, Laurie Harold, Muhammad Wasif Saif

Yale University School of Medicine. New Haven, CT, USA

ABSTRACT

Context 5-fluorouracil (5-FU) is an antimetabolite that acts during the S phase of the cell cycle. Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the pathway that catabolises the pyrimidines. 5-fluorouracil and its oral prodrug capecitabine are used in the treatment of a number of solid tumors, including colorectal, breast, gastric, pancreatic, prostate, and bladder cancers. Common side effects include leukopenia, diarrhea, stomatitis, nausea, vomiting, and alopecia. Cardiotoxicity is a relatively uncommon side effect of 5-fluorouracil and capecitabine.

Case report This article reports the case of a 63-year-old male with locally invasive pancreatic cancer who developed recurrent chest pain and ischemic electrocardiogram changes after treatment with 5-fluorouracil and capecitabine. Full sequencing of the dihydropyrimidine dehydrogenase (DPYD) gene and analysis of the thymidylate synthetase (TYMS) gene promoter region was performed. Pharmacogenetic testing revealed p453L (1358C>T) type DPYD germ line mutation. This mutation has not been reported previously in association with 5-fluorouracil induced cardiotoxicity.

Conclusion Cardiotoxicity associated with 5-fluorouracil and capecitabine administration is infrequently reported in the literature and appears to be dose and schedule dependent. Genetic variations such as polymorphic abnormality of DPYD are potential causative factors for a significant portion of serious adverse reactions to 5-fluorouracil-based therapy.


Introduction

Fluoropyrimidines have been used as a basic and perpetual part of chemotherapy for malignant tumors. 5-fluorouracil (5-FU) and its pro-drug capecitabine are being widely used in oncology for treatment of various cancers including head and neck, colorectal, breast, and pancreatic tumors [1].

Although capecitabine and 5-FU have comparable end results, capecitabine offers the advantage of convenience as it can be administered orally. Capecitabine is relatively tolerated well in terms of development of known side effects such as diarrhea, neutropenia, and alopecia although causes more cases of severe hand-foot syndrome [2].

Capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) is an oral preparation that is metabolized to 5-FU via a three-step enzymatic process. Capecitabine is first hydrolyzed by carboxylesterase in the liver to the intermediate 5'-deoxy-5-fluorocytidine (5'-DFCR) that is later metabolized to 5'-deoxy-5-fluorouridine (5'-DFUR) by cytidine deaminase. 5'-DFUR is finally converted to 5-FU by thymidine phosphorylase [3].

In addition, thymidine phosphorylase is also involved in the activation of 5-FU into fluorodeoxyuridine that will further inhibit the DNA synthesis. Concentration of thymidine phosphorylase is 3-10 times higher in tumor cells compared to healthy tissue. This can enable selective drug activation of 5-FU at the tumor site and limit systemic toxicity [4].

One of the genes considered as potential factors for 5-FU toxicity is the thymidylate synthetase gene (TYMS), which is strongly inhibited by 5-FU and considered to be the major drug target. Thymidylate synthetase catalyses the intracellular conversion of deoxyuridylate to deoxythymidylate which is the sole de novo source of thymidylate, an essential precursor for DNA synthesis [5]. The active metabolite of 5-FU, 5-fluorodeoxyuridylate (5FdUMP), binds to thymidylate synthetase and inhibits it by forming a stable ternary complex [6].

The human TYMS is polymorphic with either double or triple tandem repeats of a 28 base-pair sequence downstream of the cap-site in the 59-terminal regulatory region [7]. The TYMS genotype predicts thymidylate synthetase mRNA expression in metastasized colon tumors and normal liver tissue. It is also predicts for response and for toxicity to 5-FU. Patients with the 3R/3R genotype had significantly less response and toxicity, when compared to the 2R/2R or 2R/3R genotypes under 5-FU-based chemotherapy [8].

Finally, 5-FU is catabolized into dihydrofluorouracil by the dihydropyrimidine dehydrogenase (DPD) enzyme that is present in almost all tissues. DPD is the initial rate-limiting enzyme in the catabolism of 5-FU. Polymorphic abnormality of the dihydropyrimidine dehydrogenase (DPYD) gene is lately gaining more attention due to its impact on pharmacotherapeutic decisions.

In one study, patients with DPD deficiency experienced profound systemic toxicity in response to 5-FU [9]. The cause of this toxicity seems to be prolonged exposure to 5-FU due to decreased drug catabolism. Recent genetic studies have started to define the mutations in the DPYD gene that are responsible for the DPD-deficient phenotype [10]. In vitro studies have also shown that DPYD over-expression in cancer cell lines confers resistance to 5-FU [11].

In order to reduce effects of DPYD variation on 5-FU toxicity, there have been attempts to synthesize new fluoropyrimidine drugs in combination with drugs that inhibit DPD activity [12]. By controlling DPD activity, a new class of fluorinated pyrimidines has been developed to minimize the variability of 5-FU pharmacodynamics, to decrease 5-FU toxicity, and improve its efficacy. Recently, these drugs, referred to as DIFs (DPD inhibitory fluoropyrimidines), have brought a new era of oral 5-FU therapy [13].

Milano et al. [14] have found a significant but weak relationship between peripheral blood mononuclear cells-DPD activity and FU clearance (r=0.31), which emphasizes the need to individualize therapy and dosing appropriately.

On the other hand, few studies described a limited role for polymorphic abnormality of DPYD, especially the IVS14 + 1 G>A mutation, in 5-FU related toxicity [15, 16, 17]. Two recent studies also concluded that DPYD promoter hypermethylation is not of major importance as a prognostic factor for severe toxicity in 5-FU based chemotherapy [15, 18].

Cardiotoxicity is an unusual life-threatening side effect of 5-FU. Myocardial infarction, sudden death, unstable angina, hypotension, and pulmonary edema are most common side effects, which have been reported. Vasospasm is the most commonly suspected hypothesis as the primary mechanism of inducing cardiotoxicity. These symptoms were often observed during the late phase of administration of the drug [18, 20, 21]. Other studies also concluded that cardiotoxicity is schedule dependent [22, 23].

To date, studies showing the need to mandate routine screening for DPYD or TYMS mutations are lacking. Also, relationship between polymorphic abnormality of DPYD and 5-FU induced cardiotoxicity is unclear. We report a case of 5-FU and capecitabine induced cardiotoxicity in a patient with a novel polymorphic abnormality of DPYD.

Patient and Methods

A 63-year-old male was diagnosed with locally advanced pancreatic carcinoma. His past medical history was significant for coronary artery disease status post stent placement, deep venous thrombosis following left arthroscopic knee surgery status post inferior vena cava filter placement, history of anthracosis status post right lobectomy, chronic back pain, gout, and tobacco abuse 10 pack/year. He quit smoking one year ago.

His medication list was consistent of aspirin, colchicine, amlodipine, isosorbide mononitrate, clopidogrel, metoprolol, sublingual nitroglycerin, oxycodone, and docusate. He was occasionally drinking alcohol. His family history was significant for coronary artery disease in several family members with one case of premature cardiac death.

Abdominal CT scan showed infiltrative changes at the tail of the pancreas and at the distal transverse colon. Air fluid levels are noted within large bowel without extension to the small bowel. A fairly high grade obstruction was noted on the distal transverse colon. There is thickening of the anterior renal fascia and mild stranding around the left kidney. The liver and adrenal glands are unremarkable. The gallbladder fossa shows no abnormal findings. The kidneys show no calculi present. There is no retroperitoneal lymph node enlargement. CA 19-9 level was 1,458 U/mL (reference range: 0-29 U/mL).

He was initially treated with continuous infusion of 5-FU and radiotherapy. Treatment was complicated with fever, thrombocytopenia, and development of chest pain requiring hospital admission and cardiac evaluation.

Dipyridamole stress test was performed and showed left ventricle ejection fraction of 58%. Perfusion defect due to ischemia cannot be totally excluded and apparent defect in the inferior wall was interpreted as attenuation artifact. However, the electrocardiogram changes associated with dipyridamole infusion was strongly indicative of severe underlying coronary artery disease.

Echocardiogram showed a normal left ventricle size and contractility, normal aorta, right atrium, and mitral valve. It also showed mild pulmonic regurgitation and a mildly dilated left atrium. Subsequently, he underwent cardiac catheterization with placement of three stents and continued radiation therapy.

5-FU was replaced with capecitabine. After one week of treatment, he developed recurring chest pain and later switched to gemcitabine twice weekly. He was able to complete radiotherapy and three weeks of gemcitabine and had tolerated the medication well.

Subsequently, he was tested for polymorphic abnormality of DPYD and TYMS with TheraGuide 5-FUTM (Myriad Genetic Laboratories, Inc., Salt Lake City, UT, USA) pharmacogenetic test.

Results

Analysis consists of PCR and DNA sequencing of all 23 coding exons and approximately 690 adjacent intronic base pairs of the DPYD gene. PCR and DNA sequencing analysis is also used to report the number of 28 base pair repeats within the 5’UTR region at the TYMS gene.

Patient was found to be heterozygous for P453L (1358C>T) type DPYD germ line mutation. This mutation is predicted to result in the substitution of leucine for proline at amino acid position 453 (P453L) thus, disrupting the normal structure and function of the DPD. The proline normally found at this codon position is also evolutionarily conserved. This novel missense mutation has not been reported previously in association with 5-FU induced cardiotoxicity.

TYMS analysis identified the 2R/3R genotype. In previous studies patients with this genotype have no increased risk of 5-FU toxicity compared to the general population [8, 24, 25].

Discussion

Polymorphic abnormality of DPYD, a known pharmacogenetic syndrome associated with 5-FU toxicity, has been detected in 3% to 5% of the population. This abnormality and DPD deficiency can be identified by genetic analysis and obtaining DPD levels in the peripheral blood mononuclear cells, respectively [26].

DPYD is the gene that codes for dihydropyrimidine dehydrogenase. There are at least 34 types of DPYD variants reported to date (Table 1). The mutation IVS14 + 1 G>A, DPYD*2A is the most common mutation associated with clinical DPD deficiency [27]. This mutation was detected in 24-28% of all patients suffering from severe 5-FU toxicity [28]. Screening for this mutation may identify up to 60% of individuals with absolute DPD deficiency who are at greatest risk of toxicity [29]. Down regulation by methylation of the DPYD promoter region has been identified as one of the more important regulatory mechanisms of DPD enzymatic activity [30]. Although resistance to 5-FU depends on many factors, tumoral DPD activity is a determining factor in predicting 5-FU-responsiveness [31].

Table 1. Polymorphisms of DPYD.

Reference

Genotype

Nomenclature

Allele Frequency

Ridge et al., 1998 [40]

IVS14+1G>T

DPYD*2A

0

Celik et al., 2002 [41]

IVS14+1G>T

DPYD*2A

0.75%

Wei et al.,1996 [42]

IVS14+1G>T

DPYD*2A

2.7%

Van Kuilenburg et al., 2005 [43]

IVS11+1G>T

-

Unknown

Van Kuilenburg, 2004 [28]

100del A

-

Unknown

Seck et al., 2005 [44]

295-298delTCAT

DPYD*7

0.003%

Yamaguchi et al., 2001 [45]

812delT

-

0.46%

Van Kuilenburg et al., 2002 [46]

1039-1042delTG

-

Unknown

Ridge et al., 1998 [40]

1897delC

DPYD*3

0

Van Kuilenburg, 2004 [28]

61C>T

-

Unknown

Hsiao et al., 2004 [47]

1156G>T

DPYD*12

0

Hsiao et al., 2004 [47]

62G>A

-

0

Yamaguchi et al., 2001 [45]

74A>G

-

0.46%

Seck et al., 2005 [44]

85T>C

DPYD*9A

3.7%

Van Kuilenburg et al., 2002 [46]

257C>T

-

Unknown

Seck et al., 2005 [44]

496A>G

-

0.08%

Ezzeldin et al., 2003 [48]

545T>A

-

Unknown

Van Kuilenburg et al., 2002 [46]

601A>C

-

Unknown

Van Kuilenburg et al., 2002 [46]

632A>G

-

Unknown

Vreken et al., 1997 [49]

703C>T

DPYD*8

Unknown

Van Kuilenburg et al., 2005 [43]

731A>C

-

Unknown

Ezzeldin et al., 2003 [48]

775A>G

-

Unknown

Hsiao et al., 2004 [47]

1003G>T

DPYD*11

0

Ogura et al., 2005 [50]

1097G>C

-

Unknown

Van Kuilenburg et al., 2002 [46]

1108A>G

-

Unknown

Ezzeldin et al., 2003 [48]

1217T>C

-

Unknown

Seck et al., 2005 [44]

1218G>A

-

0.01%

Van Kuilenburg et al., 2002 [46]

1475T>C

-

Unknown

Seck et al., 2005 [44]

1601G>A

DPYD*4

0.14%

Wei et al.,1998 [51]

1627A>G

DPYD*5

35.2%

Yamaguchi et al., 2001 [45]

1627A>G

DPYD*5

0.46%

Van Kuilenburg et al., 2005 [43]

1651G>A

-

Unknown

Johnson et al., 2002 [10]

1679T>G

DPYD*13

Unknown

Yamaguchi et al., 2001 [45]

1714C>G

-

0.46%

Wei et al.,1998 [51]

2194G>A

DPYD*6

6.7%

Seck et al., 2005 [44]

2194G>A

DPYD*6

0.02%

Ogura et al., 2005 [50]

2303C>A

-

Unknown

Ezzeldin et al., 2003 [48]

2329G>T

-

Unknown

Vreken et al., 1997 [49]

2657G>A

-

Unknown

Seck et al., 2005 [44]

2846A>T

-

0.006%

Ezzeldin et al., 2003 [48]

2921A>T

-

Unknown

Van Kuilenburg et al., 2002 [46]

2933A>G

-

Unknown

Vreken et al., 1998 [52]

2983G>T

DPYD*10

Unknown

Seck et al., 2005 [44]

3067C>T

-

0.003%

Seck et al., 2005 [44]

1236G>A

-

0.003%

Yamaguchi et al., 2001 [45]

1896T>C

-

9.8%

Cardiotoxicity associated with 5-FU administration is infrequent. Recently, Spasojević et al. [32] have performed an ex vivo and in vivo study of the effects of cisplatin and 5-FU on erythrocytes, using a variety of biophysical techniques. Their research showed 5-FU provoked a pronounced decrease of the O2 level in blood and affected the metabolism of phosphate compounds, while cisplatin had no such effects. They suggested decreased oxygen transfer capacity of erythrocytes as a cause of 5-FU related ischemia.

In one study [22], 17 of 427 patients treated with 5-FU developed clinical symptoms and electrocardiographic abnormalities indicating 5-FU cardiotoxicity. Patients with continuous infusion of 5-FU had a higher incidence of cardiotoxicity. Seven of the 17 patients with 5-FU cardiotoxicity had an acute myocardial infarction, 4 developed ischemic changes, while 4 more patients had electrocardiographic abnormalities consistent with coronary vasospasm, of whom one subsequently died.

De Forni et al. [33] showed 28 of 367 patients receiving high dose 5-FU had cardiac events with only nine of them having cardiac history. Six of these patients’ cardiac symptoms returned to baseline but eight had unstable angina, eleven had hypotension, one had pulmonary edema and four had sudden death.

In another study of 1350 patients without any cardiac history [34], 5-FU administration induced chest pain in 10 patients including an infarct like pattern in two (with one death), heart failure in one patient, angina pain without electrocardiographic changes in three patients and electrocardiographic changes without any symptoms in two patients. These symptoms seem to have resolved upon discontinuation of treatment, except for one patient who died later of a cardiac infarct. This suggests that cardiotoxicity can happen even in patients with no significant cardiac history.

Jensen et al. [35] reviewed cardiotoxicity among 668 patients treated with 5-FU or capecitabine for gastrointestinal cancers and concluded 5-FU induced cardiotoxicity is only related to cardiac and renal co-morbidity. They suggested in this situation, rechallenge with modified 5-FU-based chemotherapy regimen supported by symptomatic medical treatment is feasible. Unfortunately, pharmacogenetic testing was not performed in any of these studies.

Although 5-FU associated cardiotoxicity is not clearly understood, polymorphic abnormality of DPYD is theorized as a plausible cause. Milano et al. [36] reported one case of 5-FU related cardiotoxicity in 19 patients with polymorphic abnormality of DPYD (5%).

There have been reports of capecitabine related cardiotoxicity. Toxicity with this drug ranged a wide spectrum with different mechanisms, from coronary vasospasms [37] to acute coronary syndrome [38]. Frickhofen et al. [39] reported a case of acute coronary syndrome following treatment of both 5-FU and capecitabine. They have recommended against using this prodrug if a previous toxicity with 5-FU has been observed.

Conclusion

Association between DPYD variants and 5-FU related cardiotoxicity is unclear. Adequate predictive models and pharmacogenetic testing should be identified to establish a possible relationship between 5-FU and capecitabine induced cardiotoxicity and polymorphic abnormality of DPYD.

Previously unreported P453L (1358C>T) mutation as a novel DPYD variant which is observed in the context of 5-FU related cardiotoxicity represents an interesting candidate for further studies.

References

  1. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27:23-44. [More details]

  2. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12:131-41. [More details]

  3. Tanaka F, Fukuse T, Wada H, Fukushima M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol 2000; 1:137-64. [More details]

  4. Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, et al. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J 2007; 13:247-56. [More details]

  5. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Dushinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179:663-6. [More details]

  6. Danenberg PV. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochem Biophys Acta 1977; 473:73-92. [More details]

  7. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20:191-7. [More details]

  8. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1:65-70. [More details]

  9. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5:2006-11. [More details]

  10. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002; 8:768-74. [More details]

  11. Takebe N, Zhao SC, Ural AU, Johnson MR, Banerjee D, Diasio RB, Bertino JR. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther 2001; 8:966-73. [More details]

  12. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Williston Park) 1998; 12:23-7. [More details]

  13. Kubota T. 5-fluorouracil and dihydropyrimidine dehydrogenase. Gan To Kagaku Ryoho 2001; 28:433-9. [More details]

  14. Milano G, Etienne MC. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther Drug Monit 1996; 18:335-40. [More details]

  15. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26:2131-8. [More details]

  16. Magné N, Etienne-Grimaldi MC, Cals L, Renée N, Formento JL, Francoual M, Milano G. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol 2007; 64:237-40. [More details]

  17. Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 2006; 28:678-85. [More details]

  18. Amstutz U, Farese S, Aebi S, Largiadèr CR. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res 2008; 27:54. [More details]

  19. Grzesk G, Orzalkiewicz Z, Polak G, Przybyl R, Nartowicz E, Szadujkis-Szadurski L, Grabczewska Z. Coronary artery stenting in the treatment of 5-fluorouracil-induced unstable angina. Przegl Lek 2003; 60:46-8. [More details]

  20. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, Belkhiria M, et al. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006; 25:305-9. [More details]

  21. Van Kuilenburg AB. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest 2006; 24:215-7. [More details]

  22. Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients. Med Sci Monit 2002; 8:I51-7. [More details]

  23. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134:75-82. [More details]

  24. Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10:5880-8. [More details]

  25. Ichikawa W, Takahashi T, Suto K, Sasaki Y, Hirayama R. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12:3928-34. [More details]

  26. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, Gamelin E. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5:2895-904. [More details]

  27. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 2007; 60:503-7. [More details]

  28. Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40:939-50. [More details]

  29. Gardiner SJ, Begg EJ, Robinson BA. The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil. Adverse Drug React Toxicol Rev 2002; 21:1-16. [More details]

  30. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005; 11:8699-705. [More details]

  31. van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 2003; 40:41-5. [More details]

  32. Spasojevic I, Jelic S, Zakrzewska J, Bacic G. Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia. Molecules 2008; 14:53-67. [More details]

  33. de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10:1795-801. [More details]

  34. Tsibiribi P, Descotes J, Lombard-Bohas C, Barel C, Bui-Xuan B, Belkhiria M, Tabib A, Timour Q. Cardiotoxicity of 5-Flourouracil in 1350 patients with no prior history of heart disease. Bull Cancer 2006; 93:10027-30. [More details]

  35. Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006; 58:487-93. [More details]

  36. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999; 79:627-30. [More details]

  37. Papadopoulos CA, Wilson H. Capecitabine-associated coronary vasospasm: a case report. Emerg Med J 2008; 25:307-9. [More details]

  38. Wijesinghe N, Thompson PI, McAlister H. Acute coronary syndrome induced by capecitabine therapy. Heart Lung Circ 2006; 15:337-9. [More details]

  39. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13:797-801. [More details]

  40. Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 1998; 46:151-6. [More details]

  41. Celik I, Kars A, Guc D, Tekuzman G, Ruacan S. Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest 2002; 20:333-9. [More details]

  42. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-Fluorouracil toxicity. J Clin Invest 1996; 3:610-5. [More details]

  43. van Kuilenburg ABP, Meinsma R, Beke E, Bobba B, Boffi P, Enns GM, et al. Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function. Biol Chem 2005; 386:319-24. [More details]

  44. Seck K, Riemer S, Kates R, Ulrich T, Lutz V, Harbeck N, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005; 11:5886-92. [More details]

  45. Yamaguchi K, Arai Y, Kanda Y, Akagi K. Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 2001; 92:337-42. [More details]

  46. van Kuilenburg ABP, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJM, et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 2002; 364:157-63. [More details]

  47. Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 2004; 53:445-51. [More details]

  48. Ezzeldin H, Johnson MR, Okamoto Y, Diasio RB. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003; 9:3021-8. [More details]

  49. Vreken P, van Kuilenburg ABP, Meinsma R, De Abreu RA, Van Gennip AH. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet 1997; 101:333-8. [More details]

  50. Ogura K, Ohnuma T, Minamide Y, Mizuno A, Nishiyama T, Nagashima S, et al. Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations. Clin Cancer Res 2005; 11:5104-11. [More details]

  51. Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salquero P, Gonzalez FJ. Characterization of human dihydropyrimidine dehydrogenase gene. Genomics 1998; 51:391-400. [More details]

  52. Vreken P, van Kuilenburg ABP, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJJ, et al. Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. Coli. J Inherit Metab Dis1997; 21:276-9. [More details]

Article in PDF format


Received January 5th, 2009 - Accepted January 26th, 2009

Key words capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Mutation

Abbreviations 5'-DFUR: 5'-deoxy-5-fluorouridine; DPD: dihydropyrimidine dehydrogenase; DPYD: dihydropyrimidine dehydrogenase; TYMS: thymidylate synthetase gene; P453L: proline at amino acid position 453

Conflict of interest The authors have no potential conflicts of interest

Correspondence
Muhammad Wasif Saif
Section of Medical Oncology
Yale University School of Medicine
333 Cedar Street; FMP:116
New Haven, CT 06520
USA
Phone: +1-203.737.1875
Fax: +1-203.785.3788
E-mail: wasif.saif@yale.edu

JOP Home page